Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AGL with free AI briefings, catalyst countdowns, and dilution alerts.

AGL · agilon health, inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$239.8M Cash on Hand
193.7mo Cash Runway
Follow AGL by email Get an email when AGL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AGL, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

AGL holds $239.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.7M/quarter from operations, an estimated runway of 193.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AGL files for a raise →

👥 Who Owns AGL

Insiders 11.2% Institutions (259 holders) 88.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Steven Sell
CEO & President, Director
Insider 943,910 5.62% 2025-04-14
Timothy Patrick O'Rourke
CEO & President, Director
Insider 320,000 1.91% 2026-05-07
Ronald A Williams
Director
Insider 149,141 0.89% 2026-06-02
Jeffrey A. Schwaneke
Chief Financial Officer
Insider 138,031 0.82% 2026-07-01
Benjamin Shaker
Chief Markets Officer
Insider 122,850 0.73% 2026-04-14
Denise Zamore
Chief Legal Officer
Insider 66,075 0.39% 2026-08-01
Sharad Mansukani
Director
Insider 56,242 0.33% 2026-06-02
Girish Venkatachaliah
Chief Technology Officer
Insider 38,236 0.23% 2026-04-14
John William Wulf
Director
Insider 16,765 0.10% 2026-06-02
Timothy Gertsch
Chief Accounting Officer
Insider 14,152 0.08% 2026-08-16
Karen McLoughlin
Director
Insider 8,207 0.05% 2026-06-02
Silvana Battaglia
Director
Insider 7,926 0.05% 2026-06-02

Share count 16,795,774 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AGL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AGL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.